S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

• N. Jain,
• P. Thompson,
• J. Burger,
• A. Ferrajoli,
• K. Takahashi,
• Z. Estrov,
• G. Borthakur,
• P. Bose,
• T. Kadia,
• N. Pemmaraju,
• K. Sasaki,
• M. Konopleva,
• E. Jabbour,
• N. Garg,
• X. Wang,
• R. Kanagal-Shamanna,
• K. Patel,
• W. Wang,
• S. Wang,
• J. Jorgensen,
• W. Lopez,
• A. Ayala,
• W. Plunkett,
• V. Gandhi,
• H. Kantarjian,
• S. O’Brien,
• M. Keating,
• W. Wierda

Affiliations

N. Jain

1 Leukemia

P. Thompson

1 Leukemia

J. Burger

1 Leukemia

A. Ferrajoli

1 Leukemia

K. Takahashi

1 Leukemia

Z. Estrov

1 Leukemia

G. Borthakur

1 Leukemia

P. Bose

1 Leukemia

T. Kadia

1 Leukemia

N. Pemmaraju

1 Leukemia

K. Sasaki

1 Leukemia

M. Konopleva

1 Leukemia

E. Jabbour

1 Leukemia

N. Garg

2 Radiology

X. Wang

3 Biostatistics

R. Kanagal-Shamanna

4 Hematopathology

K. Patel

4 Hematopathology

W. Wang

4 Hematopathology

S. Wang

4 Hematopathology

J. Jorgensen

4 Hematopathology

W. Lopez

1 Leukemia

A. Ayala

1 Leukemia

W. Plunkett

5 Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston

V. Gandhi

5 Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston

H. Kantarjian

1 Leukemia

S. O’Brien

6 Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, United States of America

M. Keating

1 Leukemia

W. Wierda

1 Leukemia